Brussels, Belgium

Julien Leveque

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Ucb Pharma, S.a.. Active years: 2011.


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Julien Leveque

Introduction

Julien Leveque is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of chemistry, particularly in the development of pharmaceutical compounds. His work has led to the creation of innovative solutions that enhance the synthesis of important medicinal substances.

Latest Patents

Julien Leveque holds a patent for sulfanyl derivatives and their use as synthesis intermediates. This patent, which is crucial for the preparation of the pharmaceutically active compound mesna, showcases his expertise in chemical synthesis. The patent details sulfanyl derivatives of formula (I), where X can be O or N—C(NH)NH, and M+ can be various ions including hydrogen, sodium, and ammonium.

Career Highlights

Julien is currently employed at UCB Pharma S.A., a leading global biopharmaceutical company. His role at UCB Pharma allows him to work on cutting-edge research and development projects that aim to improve patient outcomes through innovative therapies. His dedication to advancing pharmaceutical science is evident in his work and contributions to the field.

Collaborations

Julien collaborates with talented professionals such as Nicolas Barbarin and Magali Palacio. These partnerships enhance the research environment and foster innovation within the company.

Conclusion

Julien Leveque's contributions to the field of chemistry and pharmaceuticals are noteworthy. His patent for sulfanyl derivatives exemplifies his innovative spirit and commitment to advancing medical science. His work at UCB Pharma continues to impact the industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…